Country: SPAIN | Region: EUROPE | Type: Biosimilar | Keywords: #inflammatorydiseases #monoclonalantibodies #oncology #regulation #sefh
PRICENTRIC BRIEF:
- The Spanish Society of Hospital Pharmacists (SEFH) calculated that Spain has saved more than 2,400 million euros between 2009 and 2020 through the introduction of biosimilars for the treatment of inflammatory diseases and cancer
- In the article, published in the May/June issue of the journal Farmacia Hospitalaria, Dr. Miguel Ángel Calleja, former President of SEFH, said, “The use of monoclonal antibody biosimilars is endorsed by many scientific societies and allows additional innovation for the development of these molecules that adds value to patients and the Health System”
- Dr. Martinez Sesmero, Director of Innovation SEFH, too stressed that biosimilars represent a boost of “high value” in optimizing the management of health resources, reducing costs, increasing competitiveness and creating incentives to develop new and innovative therapeutic tools, monitoring and evaluation of health outcomes
THE DETAILS
MADRID, Spain – The Spanish Society of Hospital Pharmacists (SEFH) calculated that Spain has saved more than 2,400 million euros between 2009 and 2020 through the introduction of biosimilars for the treatment of inflammatory diseases and cancer.
SEFH published their findings in the May/June issue of the journal Farmacia Hospitalaria.
In the article, SEFH details the approval process for these monoclonal antibody biosimilars in the European Union (EU), which is based on proven quality, efficacy, safety, and biosimilarity.
Dr. Miguel Angel Calleja, former President of SEFH, said, “The use of monoclonal antibody biosimilars is endorsed by many scientific societies and allows additional innovation for the development of these molecules that adds value to patients and the Health System.
“It is very important that the application in hospitals is carried out with the highest degree of consensus between pharmacy services and colleagues from other specialties.”
Dr. Martinez Sesmero, Director of Innovation SEFH, stressed that biosimilars represent a boost of “high value” in optimizing the management of health resources, reducing costs, increasing competitiveness and creating incentives to develop new and innovative therapeutic tools, monitoring and evaluation of health outcomes.
Learn more about Pricentric ONE and our Global Pricing Solutions!
Contact us with your questions and global pricing needs, and an expert will follow up shortly.